Septerna (NASDAQ:SEPN) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Septerna (NASDAQ:SEPN) in a report published on Tuesday morning, Marketbeat reports. The brokerage issued an overweight rating and a $38.00 target price on the stock.

SEPN has been the topic of a number of other research reports. TD Cowen initiated coverage on shares of Septerna in a research report on Tuesday. They issued a “buy” rating on the stock. Wells Fargo & Company began coverage on shares of Septerna in a report on Tuesday. They issued an “overweight” rating and a $43.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on Septerna in a report on Tuesday. They set an “overweight” rating and a $50.00 price objective for the company.

Septerna Stock Performance

SEPN opened at $24.20 on Tuesday. Septerna has a 1 year low of $18.62 and a 1 year high of $26.34.

Insider Activity at Septerna

In related news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the company’s stock in a transaction on Monday, October 28th. The shares were bought at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the transaction, the insider now owns 6,215,591 shares in the company, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.